BLCM - Watch for Continued Gains in Shares of Bellicum Pharmaceuticals Inc. (BLCM)

Shares of Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) traded at a new 52-week high today of $23.11. This new high was reached on above average trading volume as 67.8 million shares traded hands, while the average 30-day volume is approximately 34,000 shares.

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.

Bellicum Pharmaceuticals Inc. has overhead space with shares priced $1.96, or 1.0% below the average consensus analyst price target of $1.98.

Bellicum Pharmaceuticals Inc. share prices have moved between a 52-week high of $4.04 and the current low of $0.72 and are currently at $1.96 per share.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer